Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Drugs that target angiogenesis

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Forecast growth rates for the oncology market.
Figure 2: Newly diagnosed cases of all cancers in the United States.
Figure 3: Forecast sales for cancer drugs by product class.

Author information

Authors and Affiliations

Authors

Related links

Related links

DATABASES

Cancer.gov

colon cancer

LocusLink

bFGF

calmodulin

COX-2

FLK1

PDGF

VEGF

Medscape DrugInfo

Regranex

thalidomide

OMIM

psoriasis

rheumatoid arthritis

stroke

FURTHER INFORMATION

National Institutes of Health

The Angiogenesis Foundation

US Food and Drug Administration

Rights and permissions

Reprints and permissions

About this article

Cite this article

Featherstone, J., Griffiths, S. Drugs that target angiogenesis. Nat Rev Drug Discov 1, 413–414 (2002). https://doi.org/10.1038/nrd824

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd824

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing